

I. AMENDMENTS

Please enter the following amendments without prejudice or disclaimer.



In the claims:

Please cancel claims 1, 2, 17 and 20.

In claims 6, 7, 9 and 14, please delete "1, 2 or".

In claim 8, please delete "2" and insert --3-- therefor and delete "said" and insert --a-- therefor.

In claims 13 and 15, please delete "2 or".

Sub C
a
3. (Amended) A method of treating a disease in a mammal wherein said method comprises co-administering of RPE cells with cells that supply a therapeutic protein or other biologically active molecule, wherein said cells that supply a therapeutic protein or other biologically active molecule are allogeneic or xenogeneic to the mammal and wherein said RPE cells are administered in an amount effective to create an immunologically privileged site and said cells that supply a therapeutic protein or other biologically active molecule are administered in an amount effective to sustain a therapeutic effect.

C
4. (Amended) The method of Claim [2 or] 3 wherein said therapeutic protein or other biologically active molecule ~~consist~~ ^{consists} of a growth factor, cytokine, hormone, peptide fragment of a hormone, inhibitor of cytokines, [peptide growth or] differentiation factor[, interleukin, chemokine, interferon,] or neurotransmitter[, colony stimulating factor or angiogenic factor].

Sub C
a
16. (Amended) A pharmaceutical composition comprising RPE cells and cells that produce a therapeutic protein or other biologically active molecule, wherein said RPE cells are allogeneic or xenogeneic to the cells that produce the therapeutic protein or other biologically active molecule, and a pharmaceutically acceptable carrier.

Sub C4
18. (Amended) A pharmaceutical composition comprising RPE cells and cells that produce a therapeutic protein, or other biologically active molecule, are attached to a matrix, wherein said RPE cells are allogeneic or xenogeneic to the cells that produce the therapeutic protein or other biologically active molecule.

19. (Amended) The composition of Claim 16 or 18 wherein therapeutic protein, or other biologically active molecule consists of a growth factor, cytokine, hormone, peptide fragment of a hormone, inhibitor of cytokines, [peptide growth or] differentiation factor or neurotransmitter [, interleukin, chemokine, interferon, colony stimulating factor or angiogenic factor].

Sub C5
23. (Amended) An article of manufacture comprising a packaging material, cells that produce a therapeutic protein or other biologically active molecule contained within said packaging material and RPE cells contained within said packaging material, wherein said RPE cells are allogeneic or xenogeneic to the cells that produce the therapeutic protein or other biologically active molecule, wherein said RPE cells are effective for creating an immunologically privileged site in a mammal, and wherein said packaging material contains a label that indicates that said RPE cells can be used for creating an immunologically privileged site in a mammal.

✓
Please add the following new claims:

25. (New) The method of Claim 4 wherein said therapeutic protein or other biologically active molecule ^{consists} ~~consist~~ of an interleukin, chemokine, interferon, colony stimulating factor or angiogenic factor.